Core Viewpoint - Tianli International Holdings (01773) demonstrates confidence in its business outlook through share purchases by its executive director and share buybacks, indicating a commitment to enhancing shareholder value [1][2] Group 1: Share Purchase by Executive - The executive director, chairman, and CEO, Mr. Luo, purchased a total of 3.8 million shares on the open market on February 20, 2026, representing approximately 0.18% of the company's issued shares at an average price of HKD 2.64 per share [1] - Following this purchase, Mr. Luo holds a total of 933 million shares, accounting for about 44.64% of the company's issued shares as of the announcement date [1] - Mr. Luo has also been granted 30 million share options under the share option plan, which are not yet exercised as of the announcement date [1] Group 2: Share Buyback - On February 20, 2026, the company repurchased a total of 200,000 shares on the open market, which constitutes approximately 0.0095% of the company's issued shares, and these repurchased shares will be held as treasury shares [1] - The board believes that conducting share buybacks under current market conditions reflects the company's confidence in its business outlook and will ultimately benefit the company and create value for shareholders [2] - The company may consider further share repurchases in the future, subject to applicable laws and regulations [2]

Group 1 - The company announced that its executive director, chairman, and CEO, Mr. Luo, purchased a total of 1 million shares in the open market on February 6, 2026, representing approximately 0.05% of the company's total issued shares of 2.109 billion shares at an average price of about HKD 2.72 per share [1] - Following the purchase, Mr. Luo holds a total of 927 million shares, which accounts for approximately 44.32% of the company's total issued shares as of the announcement date, excluding 13.227 million shares that have been repurchased but not yet canceled and 5.3 million shares held as treasury stock [1] - Mr. Luo has also been granted 30 million share options under the share option scheme, which allows him to subscribe for 30 million shares, although these options have not been exercised as of the announcement date [1] Group 2 - The board believes that the share buyback under the current market conditions demonstrates the company's confidence in its business outlook and prospects, ultimately benefiting the company and creating value for shareholders [2] - The share buyback is conducted when deemed appropriate and in the overall interest of the company and its shareholders, with the possibility of further repurchases in accordance with applicable laws and regulations [2]

Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Ms. Li Fangyu, in the future development of the company through her acquisition of 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] Group 1: Share Acquisition - Ms. Li Fangyu increased her stake in the company by acquiring 41,500 ordinary shares through LIFY Management Holdings Limited in the open market [1] - The company repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Group 2: Management Confidence - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board expresses confidence that the share repurchase demonstrates management's strong belief in the long-term value of the enterprise, which is beneficial for enhancing the company's market value and shareholder return capabilities [1] - The share repurchase aligns with the overall interests of the company and its shareholders [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) demonstrates strong confidence in its future development through share buybacks and insider purchases, indicating a belief that current share prices do not reflect the company's intrinsic value [1] Group 1: Insider Transactions - Non-executive director Yi Lin purchased a total of 61,000 shares in the open market on October 24, 2025, using personal funds, reflecting a strong belief in the company's future prospects [1] Group 2: Share Buyback Activity - On October 30, 2025, the company repurchased 30,000 shares at a total cost of approximately 927,150 HKD, with an average price of about 30.91 HKD per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 475,000 shares for a total consideration of approximately 15,069,220 HKD [1] Group 3: Management's Perspective - The board believes that the current trading price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board asserts that the share buyback reflects management's strong confidence in the long-term value of the enterprise and is beneficial for enhancing the company's market value and shareholder return capabilities [1]

Core Viewpoint - The company, 加科思药业, has demonstrated strong confidence in its fundamentals and long-term growth prospects through significant share buybacks and insider purchases by its CEO and associates [1] Group 1: Stock Performance - 加科思-B (01167) shares rose over 3%, specifically by 3.28%, reaching HKD 9.45, with a trading volume of HKD 30.1853 million [1] Group 2: Insider Transactions - The company's chairman and CEO, Dr. Wang Yinxiang, along with associates, invested nearly HKD 100 million to purchase over 11.05 million shares [1] Group 3: Share Buyback Program - The previously announced HKD 100 million share buyback program has commenced, with approximately HKD 26.7 million executed so far, and it is expected to continue over the next year [1] Group 4: Business Operations and Product Pipeline - The company reported that its business operations are currently in good condition, with encouraging progress in the development of its core product pipeline, including the Pan-KRAS inhibitors [1]

Core Viewpoint - The company demonstrates strong confidence in its future development prospects, as evidenced by significant share purchases by concerted action members and a share buyback plan [1][2] Group 1: Share Purchases - Concerted action members have collectively purchased 11.05865 million shares at a total cost of approximately 96.34 million HKD since July 16, 2025 [1] - As of the announcement date, these members hold about 200.2 million shares, representing 25.28% of the company's total issued shares [1] - The members express confidence in the company's overall development prospects, growth potential, and long-term investment value [1] Group 2: Share Buyback Plan - The board has approved a share buyback plan not exceeding 100 million HKD, believing that the current share price does not reflect the company's actual value [1] - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of 2.67 million HKD [1] - The company will continue to monitor market conditions and may exercise shareholder authorization for further share repurchases [1] Group 3: Business Operations and Product Pipeline - The board believes that the company's current business operations are in good condition, with encouraging progress in the development of core product pipelines, including but not limited to Pan-KRAS inhibitors [2] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [2]

Core Viewpoint - The company, 加科思-B (01167), has received notification from its concerted action members expressing strong confidence in the company's future development prospects, leading to significant share purchases and a share buyback program [1] Group 1: Share Purchases - From July 16, 2025, to the date of the announcement, concerted action members have collectively purchased 11,058,650 shares at a total cost of approximately HKD 96.34 million [1] - As of the announcement date, these members hold a total of 200 million shares, representing about 25.28% of the company's total issued shares [1] Group 2: Share Buyback - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of HKD 2.67 million [1] - The company plans to continue monitoring market conditions and may exercise shareholder authorization for further share repurchases based on market circumstances [1] Group 3: Business Outlook - The company reports that its current business operations are performing well, with encouraging progress in the research and development of its core product pipeline, including the Pan-KRAS inhibitor [1] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [1]

Core Viewpoint - Tianli International Holdings (01773.HK) announced that its Executive Director, Chairman, and CEO, Mr. Luo Shi, purchased 2 million shares of the company at an average price of approximately HKD 3.83 per share, representing about 0.09% of the total issued shares [1] Group 1 - Following the purchase, Mr. Luo holds a total of 907,455,569 shares, accounting for approximately 43.02% of the company's total issued shares as of the announcement date [1] - Mr. Luo expressed confidence in the business outlook and does not rule out the possibility of further increasing his shareholding at an appropriate time, subject to applicable laws and regulations [1] Group 2 - On the same date, the company repurchased 1.59 million shares, which is about 0.08% of the total issued shares [1] - The board believes that the share repurchase under current market conditions demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] - The company may consider further share repurchases in accordance with all applicable laws and regulations at an appropriate time [1]

Group 1 - Xin Feng Ming's controlling shareholder plans to increase its stake in the company with an investment of between 200 million to 300 million yuan within one year [1] - The increase in shareholding reflects confidence in the company's future development and is expected to have a positive impact on the stock price [1] - However, there are risks associated with market fluctuations that may prevent the plan from achieving its intended results [1] Group 2 - Zijin Mining has completed its share repurchase plan, spending approximately 1 billion yuan to buy back 64.316 million shares, which is 0.24% of its total share capital [2] - The repurchase was conducted at an average price of 15.55 yuan per share, slightly below the current market price, which may provide some support for the stock price [2] - Zijin Mining has announced a new repurchase plan with a budget of 600 million to 1 billion yuan [2] Group 3 - Satellite Chemical plans to repurchase shares with a budget of between 200 million to 400 million yuan to implement employee stock ownership plans or other equity incentive plans [3] - This repurchase plan indicates the company's focus on employee incentives and recognition of its own value [3] - The impact of the repurchase on the stock price is anticipated to be positive, but the actual effect will depend on market reactions and the company's future performance [3]

Group 1 - The core viewpoint of the announcements is that the management of Hars (002615) demonstrates confidence in the company's future development and long-term value through share buyback and shareholding increase plans [1][2] Group 2 - On April 8, Hars announced that its controlling shareholder's concerted actors plan to increase their shareholding by an amount not less than 6 million yuan and not exceeding 12 million yuan within six months [1] - The increase in shareholding is based on the confidence in the company's sustainable development and long-term investment value, aiming to enhance investor confidence and protect the interests of investors [1] - The increase plan does not set a fixed price range, indicating the flexibility of the shareholders in responding to market conditions and their firm belief in the company's value [1] Group 3 - On April 9, the chairman of Hars proposed a share buyback plan, with a total amount not less than 80 million yuan and not exceeding 160 million yuan, to be funded by the company's own or self-raised funds [2] - The buyback shares will be used for future equity incentive plans or employee stock ownership plans, with any unused shares to be canceled if not utilized within 36 months [2] - The chairman has committed to supporting the buyback plan and has not engaged in buying or selling company shares in the past six months, reflecting a strong commitment to the plan [2] Group 4 - For the first three quarters of 2024, Hars achieved operating revenue of 2.367 billion yuan, a year-on-year increase of 38.77%, and a net profit of 225 million yuan, a year-on-year increase of 47.03% [3] - According to Haitong Securities research, Hars' multi-brand strategy covers different customer groups, and with increased investment in its own brands, steady growth is expected for these brands [3]